Biocon's cancer drug gets USFDA nod, but investors remain cautious

Biocon was trading on the BSE at ₹295.15 at 9:29 a.m., down ₹3.60, or 1.21 %.

from IIFL Securities https://ift.tt/FPeb05d
via IFTTT